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Abstract  45 
Background: Canine idiopathic eosinophilic lung disease (ELD) is sparsely documented in 46 
the literature.  47 
Methods: Clinical presentation and outcome of dogs diagnosed with ELD(eosinophilic 48 
bronchitis or eosinophilic bronchopneumonia) were reviewed. Subgroups were made based on 49 
chronicity of clinical signs and findings of thoracic imaging: NCI (no changes in thoracic 50 
imaging), BRON (bronchial/peribronchial pattern), INT (Bronchointerstitial/Interstitial/alveolar).  51 
Results: Seventy cases were included. There were more young to adult, crossbreed and 52 
female dogs. Compared to the other two groups NCI dogs showed lower BALF eosinophilic 53 
pleocytosis and absence of circulating eosinophilia, bronchiectasis or death due to respiratory 54 
disease.All dogs responded clinically to corticosteroids. Median treatment duration was 4 55 
months. Remission (no clinical signs after treatment discontinuation for >1 month) and long-56 
term remission (>6 months) was achieved in 60%, and 51% of patients respectively. Relapse 57 
occurred in 26% of cases after remission but was rare (3%) after long- term remission. The 1,2, 58 
and 4-year survival to death due to respiratory disease was 98%, 97% and 91% respectively.  59 
Conclusion: Prognosis and initial clinical response for ELD was generally good although 60 
achievement of long-term remission was only seen in 51% of dogs. Different outcomes based 61 
on chronicity of signs, corticosteroid dose, thoracic imaging abnormalities and other clinical 62 
variables were not appreciated.  63 
Keywords: Eosinophilic bronchopneumopathy; Eosinophilic bronchitis; Asthma; Endoscopy  64 
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INTRODUCTION: 66 
Eosinophilic lung disease (ELD) is well-recognized in both human and veterinary 67 
medicine and is characterized by eosinophilic infiltration into the airways or the pulmonary 68 
parenchyma. Sub-classification has previously been suggested for the dog based on the human 69 
classification system and is centred around the affected location (airways vs parenchymal) and 70 
the underlying aetiology. [1,2,3,4] ELD has been associated in some instances with parasitic 71 
pneumonitis, airway foreign bodies, neoplasia or systemic eosinophilic disease. However, in 72 
most instances no underlying aetiology is identified, and the disease is termed idiopathic: i.e. 73 
idiopathic eosinophilic bronchitis (EB) or idiopathic eosinophilic bronchopneumopathy (EBP). 74 
[1,2,5,6,7,8,9] 75 
 It is suspected that hypersensitivity plays a role in these cases, but the exact mechanism 76 
has not been fully elucidated. [1,5,6,7,8,10] EBP and EB are categorized as separate processes in 77 
the human classification [1,3,11], but most of the previous retrospective studies of canine 78 
idiopathic ELD have described the disease as EBP and have combined cases with primarily 79 
bronchial, peri-bronchial or parenchymal disease into one population.  What constitutes EB, as 80 
a different entity to EBP, has not been historically well described in canine medicine. [1,2,9, 10, 81 
12,13,14] but a recent retrospective study reported the clinical presentation and findings of ELD 82 
dogs with a presumptive diagnosis of EB or EBP based on the severity of their bronchoscopy 83 
findings [15]. Studies separating canine ELD cases primarily by their thoracic imaging 84 
characteristics have not been reported.  85 
The two most common idiopathic eosinophilic parenchymal lung diseases in humans are 86 
idiopathic acute eosinophilic pneumonia which has an acute presentation, shows more severe 87 
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alteration in pulmonary function, occurs most commonly in younger male individuals and rarely 88 
requires long term treatment; and idiopathic chronic eosinophilic pneumonia characterized by 89 
a longer course of presentation, affecting middle-aged to older patients, often female and 90 
usually requiring long term therapy. [3,4,11] It is unknown whether similar presentations and 91 
associated responses to treatment are observed in canine ELD patients.  92 
 Previous EBP studies comprised single centres populations and have evaluated the 93 
clinical and diagnostic presentation and the short-term response to therapy 94 
[2,5,6,9,12,13,14,15,16]. Corticosteroid therapy is the treatment of choice. A favourable short-95 
term response with variable short-term remission and relapse rates has been reported. 96 
[1,2,9,12,14] The optimal dose of oral corticosteroids for canine ELD has not been fully 97 
elucidated. Inhaled monotherapy with fluticasone has been shown to improve clinical signs in a 98 
small single-centre study, however relapses and ongoing clinical signs were observed in the 99 
majority of the cases [14]. 100 
The aims of this paper were 1) to retrospectively describe the clinical presentation, 101 
therapeutic management, long-term follow-up and remission and survival rates of a large group 102 
of patients diagnosed with ELD in a multicentre population within the United Kingdom (UK); 2) 103 
to evaluate the differences in diagnosis and treatment between dogs with acute and chronic 104 
ELD, and among dogs with three different appearance on thoracic imaging: no changes, 105 
bronchial/peribronchial patter or interstial/alveolar patterns. 3) to investigate whether the 106 
dose of corticosteroids used (anti-inflammatory versus immunosuppressive) had an effect on 107 
outcome.  108 
MATERIALS AND METHODS 109 
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Ethical approval was obtained from the ethics board of each participating University.   110 
Records of all cases with a final diagnosis of EB or EBP diagnosed by a board-certified internist 111 
or cardiologist or a supervised resident at four university referral hospitals in the UK 112 
(Cambridge, Liverpool, Edinburgh and Bristol) between 2004 and 2016 were reviewed. Follow-113 
up for each case was acquired through the referral centre or via the referring veterinarian’s 114 
medical records. Cases were only considered if they had a full medical record available for 115 
review, presence of clinical signs suggestive of pulmonary disease (coughing, dyspnoea or 116 
tachypnoea), thoracic imaging at diagnosis, complete bronchoscopic examination, 117 
bronchoscopy-guided bronchoalveolar lavage fluid (BALF) analysis and eosinophilic pleocytosis 118 
on BALF results. Eosinophilic pleocytosis was defined as > 10% of the leukocyte differential 119 
comprising of eosinophils, with neutrophils accounting for <10%. If neutrophils were >10% the 120 
eosinophilic component had to be substantially higher. For cases to be included, parasitic 121 
disease had to have been ruled out by one or a combination of: a negative faecal analysis, 122 
absence of parasites on BALF analysis or previous regular veterinary approved anti-parasitic 123 
therapy. No case had a history of travel outside the UK. Cases were also excluded if any other 124 
underlying cause of ELD such as parasitic pneumonitis was identified.  125 
The following information was retrieved for each case: signalment, weight, presence of 126 
circulating eosinophilia, thoracic imaging findings, bronchoscopy report, BALF cytology results, 127 
infectious disease screening results, concurrent diseases, clinical signs and their duration prior 128 
to diagnosis, treatment prior to diagnosis or referral.  129 
 8 
Patients with clinical signs < 1 month were categorized as acute and those with clinical signs > 1 130 
month categorized as chronic, similar to the criteria used for human idiopathic eosinophilic 131 
pneumonia (11).  132 
 Thoracic imaging was performed by radiography, computed tomography (CT) or both. 133 
All images were reviewed by a board-certified specialist in diagnostic imaging or a resident 134 
working under his/her supervision, and sub-classified based on the final report as: no 135 
pulmonary abnormalities or pulmonary abnormalities (bronchial/peri-bronchial, interstitial, 136 
alveolar) (Figure 1, 2 and 3). CT was used in preference to radiography when both modalities 137 
were available. Patients without pulmonary abnormalities were grouped as NCI, and those with 138 
pulmonary abnormalities as BRON (if a bronchial/peribronchial pattern was present) or INT (if 139 
bronchointerstitial/interstitial/alveolar patterns were present).  140 
Bronchoscopy was performed in all patients and reported abnormalities were described 141 
as: erythema, oedema, mucus, presence of proliferative changes, bronchiectasis or bronchial 142 
collapse (Figure 4,5 and 6). Bronchoscopy findings were subjectively scored based on evaluation 143 
of the number of those abnormalities present and graded as: mild (0 - 1 abnormalities), 144 
moderate (2-3) or severe (> 4) [2]. BALF was analysed by a board-certified clinical pathologist or 145 
a resident under their supervision. BALF results were graded, as previously published [2], based 146 
on the degree of eosinophilic pleocytosis: Grade 1-mild- (10-20% eosinophils), grade 2-147 
moderate- (21-50% eosinophils), grade 3-severe-(>50% eosinophils) (Figure 7).  148 
Screening for concurrent infectious bacterial respiratory disease was recorded: BALF 149 
bacterial culture, Bordetella bronchiseptica PCR, Mycoplasma spp. PCR or culture.  150 
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Treatment (dose, duration and route administered) was recorded for each patient. Patients 151 
receiving oral corticosteroids were dichotomized based on their dose of prednisolone into anti-152 
inflammatory or immunosuppressive groups: patients needing ≤1mg/kg per day or below to 153 
control their clinical signs were classified as group A (anti-inflammatory), and patients receiving 154 
> 1mg/kg at some point during the treatment were classified as group I (immunosuppressive). 155 
Total response was defined as resolution of clinical signs, partial response as improvement of 156 
clinical signs and treatment failure as no improvement of clinical signs. Remission and long-157 
term remission were defined as the full absence of respiratory signs following discontinuation 158 
of corticosteroid administration for >1 month and >6 months respectively. Relapse was defined 159 
as reoccurrence of clinical signs during remission. Time to remission, length of remission and 160 
survival were recorded.  161 
Statistical analysis: 162 
Data were entered into a spreadsheeta and statistical analyses was performed using two 163 
statistical software programs.b,c The level of significance was set at 5% for all analyses. Gaussian 164 
distribution was assessed graphically and then with the Shapiro-Wilk test. Baseline descriptive 165 
statistics were calculated and reported as percentages for categorical data and median and 166 
interquartile range for continuous data. 167 
Group comparisons for continuous data were performed with t-test, Mann-Whitney U or 168 
Kruskal-Wallis test and chi-square or Fisher’s exact test to compare proportions as indicated; no 169 
attempt was made to correct for multiple comparisons. Group comparisons were made and are 170 
outlined in table 1,2 and 3. When statistical differences were carried out for 3x2 and 3x3 tables 171 
further post-hoc analysis was carried out when necessary by looking at the adjusted 172 
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standardised residuals and carrying out smaller 2x2 direct comparisons to determine specific P 173 
values.  174 
Time to event analysis was carried out for reaching remission and long-term remission. Kaplan-175 
Meier survival curves were constructed to assess time to remission and time to long term 176 
remission between groups and the log rank test was used to compare these. Those not 177 
achieving remission, or these lost to follow-up were right censored according their follow-up 178 
period. Achievement of remission and the probability of achieving remission and long-term 179 
remission was further investigated for other numerous variables (table 3).  180 
RESULTS 181 
Population 182 
Of the 95 cases initially evaluated, 70 met the inclusion criteria and were enrolled. The 183 
25 cases excluded were due to parasitic pneumonitis (2), incomplete investigations (4), 184 
complete resolution of signs with anthelminthic treatment (1), and incomplete medical 185 
histories (18). Patients comprised of the following breeds: Crossbreed (17), Labrador (7); 186 
Springer Spaniel (5); Jack Russel Terrier (5); Cocker Spaniel (4); Siberian Husky (4); Border Collie 187 
(2); Border terrier (2); Irish Setter (2); Lakeland terrier (2); Shih Tzu (2); Weimaraner (2); 188 
Northern Inuit (2); Parsons Russel terrier (2); followed by one each of the following breeds: Toy 189 
poodle, Beagle, Bedlington Terrier, Boxer, Chihuahua, Portuguese Podengo, Maltese, 190 
Newfoundland, Golden Retriever, Standard Poodle, Italian Greyhound, Rottweiler. Within the 191 
cross-breed group 2/13 (12%) were in the IM-group, 6/17 (35%) within the BRON group and 192 
9/17 (53%) within the INT group.  193 
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Median age was 4 years (IQR 1-6 years). There were 63% (44/70) females, of these 80% 194 
(35/44) were neutered, and 37% (26/70) males, of these 69% (18/26) were neutered. Median 195 
weight was 16.4 kg (IQR 9.4-27 kg). 196 
Clinical signs prior to diagnosis were present for a median duration of 2 months (IQR 1-6 197 
months). 48/70 dogs (70%) had clinical signs of > 1-month duration (chronic), and 22/70 dogs 198 
had clinical signs lasting < 1 month (acute) (Table 1).  199 
Table 1 200 
 All (n=70) NCI (n=13) BRON 
(n=19)  
INT (n=38) P values
a 
Acute 
(n=22) 
Chronic (n=48) P values
b 
Age (years) 4 (1-6) 4 (2-6) 4 (2-6) 3 (1-6) P=0.733 4 (2-6) 2.5 (1-6) P=0.150 
Weight (kg) 16.4 (9.4-27) 15 (9.8-24) 16.5 (9.5-
21.5) 
16.8 (9.4-
29) 
P=0.865 14.3 (9.4-
28.35) 
16.6 (9.8-27) P=0.810 
Circulating eosinophilia
 
36% (25/70)
c 
0% (0/13) 32% (6/19) 50% 
(19/38) 
P=0.005
a,d 
59% 
(13/22) 
25% (12/48) P=0.006
b 
Bronchiectasis 14% (10/70) 0% (0/13) 16% (3/19) 18% (7/38) P=0.255 18% (4/22) 13%(6/48) P=0.528 
Bronchoscopy score  
(mild, moderate, severe) 
37% (25/68), 
54% (37/68), 
9% (6/68)
e 
46% (6/13), 
54% (7/13), 
0% (0/13) 
32% (6/19) 
53% 
(10/19) 
15% (3/19) 
 
36% 
(13/38) 
56% 
(20/38) 
8% (3/38) 
P=0.613 38% (8/21), 
52% 
(11/21), 
10% (2/21) 
36% (17/47), 
55% (26/47), 
9% (2/47) 
P=0.892 
Degree of eosinophilia 
on BALF (mild, 
moderate, severe) 
10% (7/70), 
29% (20/70), 
61% (43/70)
f 
23% (3/13), 
54% (7/13), 
23% (3/13) 
5% (1/19) 
21% (4/19) 
74% 
(14/19) 
8% (3/38), 
23% (9/38), 
69% 
(26/38) 
P=0.021
g 
9% (2/22), 
27% (6/22), 
64% 
(14/22) 
10% (5/48), 
29% (14/48), 
60% (29/48) 
P=0.965 
AI  46% (31/67) 62% (8/13) 53% (9/19) 50% 
(18/38) 
P=0.419 50% 
(11/22) 
52% (25/48) P=0.871 
IM  54% (36/67) 23% (3/13) 47% (9/19) 50% 
(19/38)  
P=0.229 50% 
(11/22) 
42% (20/48) P=0.515 
Oral and inhaled 
steroids 
36% (25/67) 38% (5/13) 42% (8/19) 34% 
(13/38) 
P=0.448 32% (7/22) 37.5 % (18/48 P=0.645 
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 201 
Table 1.  202 
A breakdown of the different clinical parameters by the different subgroups can be found. 203 
When statistical significance is reached the P value appears in bold. NCI: Cases with no 204 
abnormalities on thoracic imaging. BRON: Cases with bronchial pattern on thoracic imaging. 205 
INT:  Cases with bronchointerstitial/interstitial and/or alveolar pattern on thoracic imaging. 206 
Acute: Cases with presenting clinical signs lasting less than 1 month. Chronic: Cases with 207 
presenting clinical signs lasting more than 1 month. AI: Anti-inflammatory corticosteroid. IM: 208 
Immunosuppressive corticosteroid. BALF: Bronchoalveolar lavage fluid.  209 
aThere was no difference (P=0.547) in the percentage of dogs receiving previous corticosteroids 210 
within the imaging subgroups (NCI 3/10 23%; BRON 3/19 16%; INT 11/38 28%).  211 
b More dogs in the chronic group (15/48; 31%) received steroids prior to referral than in the 212 
acute group (2/22; 9%) P=0.045. If these dogs were excluded from the analysis eosinophilia was 213 
still significantly different between both groups (P=0.018) and no difference was observed for 214 
any of the other studied variables (All P values higher than 0.150).  215 
cThere was no difference (P=0.228) in the percentage of dogs with eosinophilia for those dogs 216 
who had (4/17; 24%) vs had not (21/53; 39%) received previous corticosteroids. 217 
dNCI vs BRON P=0.025; NCI vs INT P= 0.001; NCI vs INT P=0.186 218 
eThere was no difference (P=0.577) in the severity of bronchoscopy findings severity between 219 
dogs receiving (8/17 47%; 8/17 47%; 1/8 6%) or not receiving (17/51 33%; 29/51 57%; 5/51 220 
10%) previous corticosteroids.  221 
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fThere was no difference (P=0.951) in eosinophilic pleocytosis in BAL severity between dogs  222 
receiving (2/17 12%; 5/17 29%; 10/17 59%) or not receiving (5/53 9%; 15/53 28%; 33/53 62%). 223 
previous corticosteroids.  224 
gNCI vs BRON P=0.016; NCI vs INT P=0.017; BRON vs INT P=0.890 225 
History and physical examination findings 226 
Clinical signs in patients prior to referral included cough (94%; 66/70), exercise 227 
intolerance (17%; (12/70), dyspnoea (16%; 12/70), tachypnoea (14%; 9/70), lethargy (13%; 228 
9/72) and nasal/nasopharyngeal signs (10%; 7/70).   229 
A minority of patients (7%;5/70), had not received any medical treatment prior to diagnosis, 230 
and the remainder (93%; 65/70) had received various combinations of medical treatment 231 
including antibiotics (81%; 57/70), non-steroidal anti-inflammatory drugs (33%; 23/70), 232 
corticosteroids (24%; 17/70), mucolytic therapy (3%; 2/70) and anthelminthic treatment (76%; 233 
53/70) prior to referral.  234 
Diagnostic investigations: 235 
Circulating eosinophilia was reported in 36% (25/70) of patients (Table 1). Faecal 236 
analysis was performed in 54% (38/70) patients (Baermann technique (24/38), Zinc floatation 237 
(10/38), and direct faecal examination (4/38)). Isopora spp. was found in one patient, but not 238 
considered to be associated with ELD and this patient was therefore included.  239 
All patients had thoracic imaging performed. Thoracic radiographs were obtained from 54% 240 
(38/70) patients and thoracic CT from 56% (39/70) patients with both modalities performed in 241 
11% (8/70). Diagnostic imaging reports identified a bronchial/peri-bronchial pattern in 27% of 242 
patients (19/70), parenchymal (interstitial or alveolar) changes in 54% (38/70) and absence of 243 
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abnormalities in 19% (13/70). Two patients with an interstitial pattern had also significant 244 
parenchymal consolidation on thoracic imaging later confirmed to be canine eosinophilic 245 
pulmonary granulomatosis (EPG). Bronchiectasis was identified on thoracic imaging in 14% 246 
patients (10/70). The entire study population was subdivided in three groups: no abnormalities 247 
on thoracic imaging (NCI), bronchial/peribronchial pattern (BRON) or 248 
bronchointerstitial/interstitial/alveolar pattern (INT) (Table 1). CT was used in 77% (10/13) 249 
cases in the NCI group, in 37% (7/19) cases in group BRON and in 58% (22/38) in group INT.  250 
Full bronchoscopy reports were available for 97% of patients (68/70) with the changes 251 
being classified as mild in 38% of cases (25/68), moderate in 54% (37/68) and severe in 9% 252 
(6/68) (Table 1). 253 
The BALF results were graded as outlined above and were as follows: grade 1 (10%; 254 
7/70); grade 2 (29%; 20/70); grade 3 (61%; 43/70) (Table 1). Three dogs had concurrent 255 
elevation of neutrophils but in these dogs the neutrophil percentage was <20% and the 256 
eosinophilic component >50%.  257 
Rhinoscopy was performed in 9% (6/70) of cases and non-infectious chronic rhinitis diagnosed 258 
in 5/6 cases. The remaining case had no biopsies taken or diagnosis reached.  259 
Bacterial culture of the BALF was performed in 97% patients (68/70). It was negative in 260 
79% of cases (54/68) and positive in 21% (14/68). Mycoplasma spp. was specifically screened 261 
for in 50% patients (35/70) and was isolated in 17% of these patients (4/35). In each case when 262 
bacterial infection was identified, clinical records indicated the positive culture was considered 263 
to be due to contamination or concurrent infection. This was considered because of a scant 264 
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(semiquantitatively) growth of an organism and/or no initial response to antibiotics, and a good 265 
subsequent response to steroid therapy in the context of a BALF eosinophilic pleocytosis. 266 
Treatment 267 
In some patients, there was an initial treatment trial with fenbendazole (74%; 52/70) or 268 
antibiotics (53%; 37/70) prior to the administration of corticosteroids. No patient had 269 
resolution of clinical signs with these treatments alone.  Corticosteroids were administered to 270 
all patients either at the time of diagnosis or when they failed to respond to antibiotic and, or 271 
anthelminthic therapy.  The breakdown of corticosteroid therapy by dose and route is outlined 272 
in Figure 8.  273 
Of the patients initially receiving only oral anti-inflammatory corticosteroids, 5.6% (2/36) 274 
subsequently required an increase to an immunosuppressive dose to control their clinical signs. 275 
Overall, 24% (6/25) of patients receiving dual therapy had their oral corticosteroid therapy 276 
discontinued and were managed solely with inhaled corticosteroid monotherapy (Table 1). 277 
Overall treatment duration range was 1-103 months (median 4 months, IQR = 2-17 months). 278 
Follow-up 279 
Duration of follow-up for each case was defined as the time from referral until: the 280 
present day/they were lost to follow-up/their death. Follow-up ranged from 1 - 140 months 281 
(median 29months, IQR = 11-50 months).  During follow-up, 7% (10/70) of patients were 282 
euthanized or died. Of these 2/10 were due to progression of their respiratory disease (one 283 
patient 3 months’ and 38 months’ post-diagnosis). The remainder died or were euthanized due 284 
to non-respiratory related illnesses.   285 
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The 1,2, and 4-year survival to death due to respiratory disease was 98%, 97% and 91% 286 
respectively (Table 2).  287 
Table 2 288 
 All (n=70) NCI (n=13) BRON (n=19) INT (n=38) P values Acute (n=22) Chronic (n=48) P values 
Total response 
(Absence of 
clinical signs) 
93% (65/70) 85% (11/13) 95% (18/19) 95% (2/38) P=0.442 95% (21/22) 92% (44/48) P=0.568 
Partial response 
(Improvement 
of clinical signs) 
7% (5/70) 15% (2/13) 5% (1/19) 5% (2/36) P=0.442 5% (1/22) 8% (4/48) P=0.568 
Remission 60% (42/70) 61% (8/13) 63.2% (12/19) 58% (22/38) P=0.922 63% (14/22) 58% (28/48) P=0.674 
Long term 
remission (>6 
months) 
51% (28/55) 36.4% (4/11) 58% (7/12) 53% (17/32) P=0.533 56% (10/18) 35% (14/40) P=0.141 
1,2,4 year 
survival to 
respiratory 
disease 
98%, 97%, 
91% 
100%, 100%, 
100% 
92%, 89%, 
88% 
97%,  96%, 
92% 
N/A 94%,  92%, 
88% 
100%, 100%,  
93% 
N/A 
 289 
Table 2.  290 
A break-down of the different therapeutic response by different subgroups can be found. When 291 
statistical significance is reached the P value appears in bold. NCI: Cases with no abnormalities 292 
on thoracic imaging. BRON: Cases with bronchial/peribronchial pattern on thoracic imaging. 293 
INT: Cases with interstitial/alveolar pattern on thoracic imaging. Acute: Cases with presenting 294 
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clinical signs lasting less than 1 month. Chronic: Cases with presenting clinical signs lasting more 295 
than 1 month. N/A: Non-applicable. The n= represents the total number of cases. For some 296 
variables the number may be less than the total patient population if the full information about 297 
that case for that variable was not available.  298 
 299 
 300 
All patients showed a positive clinical response to corticosteroid therapy. Total response 301 
was observed in 93% (65/70) of cases and a partial response in 7% (5/70) of cases. Remission 302 
was achieved in 60% (42/70) of cases and long-term remission in 51% (28/55) of cases. 303 
Treatment duration was 3 months (IQR 2-5 months) and 28.5 months (IQR 16-40 months) for 304 
those achieving and not achieving remission respectively. Treatment duration for those 305 
achieving long term remission was 3 months (IQR 2-5months).  Relapse was reported in 26% 306 
(11/42) of cases, 24% (10/42) in the first six-months following discontinuation of corticosteroid 307 
treatment and in 3% (1/28) at least six-months after stopping corticosteroid therapy. (Table 2). 308 
Group comparisons and the non-parametric log rank test showed that the median time to 309 
remission was not different between any sub-groups (table 3). 310 
Table 3 311 
 Remission P Value Long term Remission P Value 
Anthelmintic prior to ref. 
(Yes/No) 
63% (35/55) / 47% (7/15) P=0.234 54% (25/46) / 33% (3/9) P=0.249 
Bronchiectasis (Yes/No) 40% (4/10) / 63% (38/60) P=0.163 40% (2/5) / 52% (26/50) P=0.609 
Eosinophilia (Yes/No) 64% (16/25) / 57% (26/45) P=0.611 71% (12/17) / 42% (16/38) P=0.051 
Bronchoscopy score   
(mild/moderate/severe) 
64% (16/25) / 60% (22/37) / 
50% (3/6)  
P=0.811 57% (12/21) / 51% (15/29) / 
0% (0/3)  
P=0.179 
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Eosinophilic grade BALF  
(mild/moderate/severe) 
70% (5/7) / 55% (11/20) / 61% 
(26/43)  
P=0.743 66% (4/6) / 44% (7/16) / 
51.5% (17/33)  
P=0.628 
Corticosteroid dose (AI/IM) 56% (20/36) / 64% (20/31) P=0.456 41% (11/27) / 61% (10/26) P=0.130 
Corticosteroid dose (AI-IN /AI+IN 
/IM) 
62% (13/21) / 48% (7/15) / 
63% (20/31) 
P=0.496 50% (7/14) / 31 % (4/13) / 
62% (16/26) 
P=0.193 
 312 
Table 3.  313 
Comparison by subgroups of achievement of remission (total response in > 1month) and long-314 
term remission (>6m of remission).  315 
When statistical significance is reached the P value appears in bold.  In dichotomous variables 316 
the percentages of remission and long-term remission achieved by both categories can be seen. 317 
For variables with three categories percentages of the three categories achieving remission or 318 
long-term remission are depicted.  319 
BALF: Bronchoalveolar lavage fluid. AI: Anti-inflammatory corticosteroid (all group) IM: 320 
immunosuppressive corticosteroid. AI-INH: Anti-inflammatory corticosteroid without inhaled 321 
therapy. AI+INH: Anti-inflammatory corticosteroid with inhaled therapy.  322 
 323 
DISCUSSION 324 
To the best of the authors’ knowledge this is the first and largest multi-centre study of 325 
idiopathic canine eosinophilic lung disease evaluating clinical features and long-term outcome. 326 
We identified a similar age of onset (most young adult) and sex predisposition (more females) 327 
in our study population to those reported in most previous publications [1,2,9,12,13,14]. Similar 328 
to a recent publication [15] crossbreed dogs were the most common breed reported. This was 329 
different to all previous studies in which crossbreeds were reported only very sporadically 330 
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[1,2,9,12,13,14]. The most commonly reported breeds in those studies included Siberian 331 
Huskies [1,2], Labradors [9] and Cocker Spaniels [12], all of which were similarly highly 332 
represented in our study. The high proportion of crossbreed dogs cannot be explained by the 333 
differences in inclusion criteria, as they were present across all imaging subgroups and all dogs 334 
in group INT (and also dogs in group BRON in some studies) would have met criteria for 335 
inclusion in previous EBP studies.  It is possible that the increased representation of crossbreeds 336 
may reflect the hospital or regional population characteristics or the increasing awareness of 337 
the disease over the past years.  338 
Previously it has been hypothesised that younger dogs with EBP may be more difficult to 339 
manage [1,17]. This was not observed in our study where a similar treatment response and 340 
remission rate was observed for younger and older dogs. 341 
Cases were also dichotomised into acute and chronic presentation, similar to the human 342 
classification [3,4,11]. In contrast to the situation in human medicine, other than acute cases 343 
having a higher incidence of circulating eosinophilia, no other significant differences were 344 
found with regards to age of presentation, severity of clinical findings or outcome. Therefore, 345 
we did not conclude that separating these two groups provided pertinent clinical information 346 
for the management and prognosis of ELD in dogs.  347 
Whether different ELD entities with pathophysiological, clinical, therapeutic and/or 348 
prognostic differences occur in dogs is currently unknown. In humans, different disease entities 349 
with different management and outcome such as pneumonias (acute and chronic), eosinophilic 350 
bronchitis, eosinophilic bronchiolitis and asthma are described [11].  In human medicine 351 
idiopathic eosinophilic pneumonia is typically associated with pulmonary abnormalities on 352 
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thoracic imaging and eosinophilic bronchitis is characterized by the absence of pulmonary 353 
abnormalities on thoracic imaging. [3,4,11] By dividing our population into three groups in 354 
regard to their imaging findings we were able to identify a population of dogs (NCI) with 355 
isolated airway disease which would represent EB. At the other side of the spectrum dogs the 356 
INT group would be truly airway-parenchymal disease (EBP) and several differences were 357 
observed between these two groups of dogs.  NCI dogs had less severe eosinophilic pleocytosis 358 
on BALF, absence of circulating eosinophilia and absence of bronchiectasis. Additionally, no 359 
dogs in this group succumbed to their respiratory disease. Considering the age and time of 360 
presentation was similar to the INT cases, it is unlikely that dogs in the NCI group represent an 361 
early stage of the disease process and this group likely constitutes true isolated airway disease. 362 
Whether the dogs in the BRON group had EB or EBP or whether they constitute a different 363 
entity is unknown. In our study they showed similar clinical and laboratory characteristics to the 364 
INT group and showed similar differences compared with the NCI group. As the BRON group 365 
was the one where CT was used less frequently (37%) it is possible that at least some of these 366 
dogs would have shown interstitial changes on CT and indeed belonged to the INT group. A 367 
recent paper [15] also attempted to separate ELD into EB and EBP. In this paper however, the 368 
definitive criteria to separate both processes were the severity of bronchoscopy findings and 369 
dogs could be classified as EB or EBP with a bronchial radiographic pattern: EB had milder 370 
bronchoscopic findings and EBP more severe ones. After classification, EB cases in that study 371 
ended being mostly cases with absence of radiographic findings, similar to our NCI group, and, 372 
similar clinical differences to the findings in our study were observed in regard to blood and 373 
BALF eosinophilia and bronchiectasis when compared to the group classified as EBP. No other 374 
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paper has attempted to separate bronchial vs parenchymal disease in canine ELD. Previous EBP 375 
papers vary in inclusion criteria and in some of them the EBP group would have encompassed 376 
just the INT group while in others both the INT and the BRON group would have been 377 
considered EBP [1,2,9,12,13,14,18,19]. Overall however, in our study, outcomes for all 378 
subgroups were not significantly different: response and remission rates were similar with the 379 
only exception that, as mentioned previously, death or euthanasia due to respiratory disease 380 
did not occur in the NCI group.  However, as death was such a rare event in our study it is 381 
difficult to make conclusions in this regard.  382 
A population which may represent a different ELD disease entity are dogs with EPG. In 383 
our patient population only two dogs, both in the INT group, were diagnosed with EPG making 384 
it challenging to draw meaningful conclusions. Historically however, dogs with EPG have been 385 
suspected to represent a more severe form of ELD with a worse prognosis [19,20,21,22]. 386 
Consistent with this perception one of the two patients in our population who succumbed to 387 
their respiratory disease had a diagnosis of EPG. A recent study [15] suggested a more 388 
favourable prognosis for dogs with EPG dogs. However, the diagnosis of EPG dogs in this study 389 
was based on a different diagnostic criteria to the usual historical EPG definition of 390 
parenchymal lung disease and pulmonary granulomas (consolidation or masses) characterised, 391 
when histopathology is performed, by a large population of eosinophils usually with 392 
macrophages and epithelioid cells [19,20,21,22]. In this recent study [15], dogs were classified 393 
as EPG if they had, on bronchoscopy, airway disease with intraluminal eosinophilic mass lesions 394 
(plugging), irrespectively of the presence or absence of parenchymal involvement on thoracic 395 
imaging.  396 
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Circulating eosinophilia, bronchoscopic findings and the degree of eosinophilic 397 
pleocytosis was similar in our study to previous EBP studies. The incidence of bronchiectasis in 398 
our population was slightly lower compared to the 26-60% reported in previous studies 399 
[2,11,13] and a slightly lower incidence of bronchiectasis persisted when only the INT group 400 
was evaluated. Bronchiectasis was not identified in any patient assigned to the NCI group. 401 
Historically the treatment of choice for EBP has been corticosteroids, and as was 402 
observed in this study, good initial responses have been reported [1,2,5,9,12,14]. 403 
Immunosuppressive therapy has been advocated for the treatment of EBP in the dog [1,2] 404 
however, up to 40% of dogs in this study had control of their clinical signs with corticosteroids 405 
administered at an anti-inflammatory dose (although 42% of these patients also received 406 
concurrent inhaled corticosteroids therapy). Of those patients starting treatment with anti-407 
inflammatory corticosteroids, 5% required an increase dose to immunosuppressive 408 
corticosteroids to achieve control of their clinical signs. There was no statistical significance 409 
when comparing corticosteroid doses between the different subgroups which would suggest 410 
the choice of anti-inflammatory or immunosuppressive dose reflected individual clinician 411 
preference and not the type or severity of the ELD.  412 
The overall remission (60%) and long-term remission (51%) rates were modest and 413 
similar among the different subgroups; and they were also similar to the remission rates 414 
reported in previous EBP publications (30-50%) [2,10]. The relapse rate in our study (26%) was 415 
also similar to previous reports (30-72%). Importantly, in our study, it was noted that if relapse 416 
occurred, it was most likely to occur during the first 6 months following discontinuation of 417 
corticosteroid therapy. Once long-term remission was achieved relapses were very rare.  418 
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Similar to previous EBP studies, death or euthanasia due to respiratory disease was a 419 
rare event in our population and 1, 2 and 4-year survival to respiratory death exceeded 90%. As 420 
death was such a rare event, no comparisons can be made among groups, however as 421 
mentioned above none of the NCI population died or were euthanized due to respiratory 422 
disease and one of the two patients that died due to respiratory disease had a diagnosis of EPG.  423 
No obvious association was observed between any of the other studied variables 424 
indicative of clinical severity (bronchiectasis, eosinophilia, bronchoscopy score, eosinophilic 425 
grade) and any of the outcome variables. There was also no difference between dogs receiving 426 
anti-inflammatory vs immunosuppressive doses of corticosteroids with regard to likelihood of 427 
remission or long-term remission. These results were also similar if the anti-inflammatory group 428 
was broken down into those with or without concurrent inhaled therapy. Therefore, a high 429 
proportion of dogs appear to achieve remission and long-term remission without using higher 430 
immunosuppressive dose which may be associated with increase risk of side effects. However, 431 
this is a retrospective paper with several limitations and further specifically designed 432 
prospective studies are needed to determine the optimal corticosteroid dose in the 433 
management of ELD. It would be of particular interest to investigate whether the remission 434 
outcomes observed in this and previous papers could be improved and whether different 435 
strategies should be instigated for EB dogs compared to EBP dogs.  436 
There are several limitations of this study. Firstly, it has the intrinsic limitations of a 437 
retrospective multi-centre study performed over a 12-year period, including non-standardised 438 
treatments and recording of clinical records and a referral population bias. We attempted to 439 
minimize this by directly contacting the owner and the referring veterinary surgeon when 440 
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needed and by collecting a large amount of data, which could counteract some of the errors. 441 
Secondly, as in every previous EBP study, response and remission is usually assessed by the 442 
owner’s perception of resolution of clinical signs and not by the objective documentation of 443 
absence of intrapulmonary disease. Treatments were not standardised, and the dose, length 444 
and protocols used varied among the different clinicians managing the cases. In our institutions 445 
anti-inflammatory doses of prednisolone are usually 0.5 to 1 mg/kg per day and 446 
immunosuppressive doses are always above 1.5-2mg/kg but scientific evidence and consensus 447 
of what dose causes immunosuppression is lacking [23]. Also, the use of mg/m2 rather than 448 
mg/kg for larger breed dogs has been anecdotally suggested. Unfortunately, we could not 449 
retrieve the fluticasone dose accurately from the notes in all cases but in our institutions 450 
fluticasone is usually started at 125ug or 250 ug twice a day for dogs <10kg or >10kg 451 
respectively and the advice is to administer the dose after placing the mask. Thirdly we carried 452 
out many statistical tests, which can lead to type I error, and a higher number of cases would 453 
have been preferable to avoid type II error. We elected not to mathematically correct the result 454 
to prevent type I error but to report all of them and analyse them critically. In this manner most 455 
significant results reported appear robust in our opinion, although caution may be elicited with 456 
the higher P values (e.g. between 0.05 and 0.010) observed. Similarly, when subgroups were 457 
compared, all the negative results showed, for the most part, very similar populations and 458 
although statistical differences might be found with a larger study population we suspect that 459 
for the majority of comparisons it is unlikely that these would be of clinical significance.  460 
Lastly, despite utilising strict inclusion criteria, inherent limitations remained. Firstly, a 461 
consensus of what constitutes eosinophilic pleocytosis in BALF of normal dogs is not clearly 462 
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defined in the current literature [1,2,10,13, 24,25]. Similar to previous EBP studies 463 
[2,7,10,13,14,16,19] we elected to consider eosinophilia >10% in BALF abnormal, however 464 
some previous studies have used a marginally higher cut off [7,10,13,14]. Secondly, chronic 465 
bacterial respiratory tract infection has been associated with a mixed cell infiltrate on BALF and 466 
theoretically could result in higher percentage of eosinophils in BALF [1]. There were however 467 
only three included cases with mixed pleocytosis and these cases all had a low proportion of 468 
neutrophils (<20%) and high proportion of eosinophils (>50%), thereby meeting the previously 469 
suggested diagnostic criteria for ELD in dogs with mixed pleocytosis [26]. Thirdly, parasitic 470 
pneumonitis is an important differential for ELD and the ruling out of this aetiology is an 471 
essential, yet challenging aspect to the diagnosis.  We elected to use the same criteria as in 472 
previous studies [1,5,6,9, 13,14] however, absolute certainty in ruling out parasitic disease 473 
cannot unfortunately be achieved.  Despite this caveat, no statistically significant difference 474 
was found between patients that had received adequate anti-parasitic therapy and patients 475 
that had not received such treatment. Fourthly, a percentage of dogs received corticosteroids 476 
prior to presentation, and this may in theory alter several findings such as the degree of 477 
eosinophilia, the bronchoscopy score or the degree of eosinophilic pleocytosis in BAL.  478 
However, although we were not able to confirm this in all cases from the notes, it is routine 479 
policy in all the hospitals involved in the study to try to stop medications at least one week 480 
before seeing the cases. Also, there was no differences in the overall percentages of 481 
eosinophilia, bronchoscopy score or degree of eosinophilic pleocytosis when dogs with previous 482 
corticosteroids were compared to those without them. The percentage of dogs in which 483 
corticosteroids was used prior to the initial appointment was also similar among dogs in the 484 
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different imaging groups and although it was significantly higher in the chronic group than in 485 
the acute group when cases with previous glucocorticoids were excluded from analysis the 486 
overall results for the three studied variables were very similar. For all these reasons we do not 487 
believe that previous use of glucocorticoids is likely to have had a significant impact of the study 488 
results.  489 
Lastly, there was a proportion of dogs where imaging classification was carried out by 490 
radiography rather than CT and this may have led to group misclassification. This was likely less 491 
relevant for the NCI group as nearly 80% of them had CT performed and specific characteristics 492 
could be observed for this group however, as mentioned above, only 37% in group BRON were 493 
diagnosed by CT and we cannot ruled out that some of these cases would have been classified 494 
as group INT if CT had been performed.  495 
In conclusion, we report the clinical presentation, therapeutic management and long-496 
term outcome of a large cohort of dogs with ELD in the UK. Dogs in this population were 497 
predominantly young, female and crossbreed. The study also showed that dogs without 498 
imaging changes, which likely represent EB, have less severe eosinophilic pleocytosis on BALF or 499 
circulating eosinophilia than dogs with parenchymal changes suggestive of EBP. Moreover, no 500 
dog within this subgroup had bronchiectasis or died due to respiratory disease. However, a 501 
noticeable difference however in response to treatment among the different imaging 502 
subclassifications or between acute and chronic presentations was not identified. A complete 503 
response was achieved in the vast majority of dogs with ELD with the use of corticosteroid 504 
therapy, and we found modest remission rates and long-term remission rates of 60% and 51% 505 
respectively. Relapses typically occurred during the first 6 months of remission but were rare 506 
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after long-term remission. In many patients, total response, remission and long-term remission 507 
is achieved with anti-inflammatory doses of corticosteroids, however a small percentage of 508 
dogs required dose increases to an immunosuppressive corticosteroid dose. Other factors, such 509 
as severity of the clinical findings or age of presentation, were also investigated in this study but 510 
found not to be significantly associated with outcome.  511 
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Leyends 594 
 595 
Figure 1.  596 
Radiography of a dog with eosinophilic lung disease showing bronchial pattern.  597 
 598 
Figure 2.  599 
Radiography of a dog with eosinophilic lung disease showing bronchointerstitial pattern. 600 
 601 
Figure 3.  602 
CT scan of a dog eosinophilic lung disease showing bronchial thickening, peribronchial 603 
infiltrations and a multifocal widespread ground glass (interstitial) pattern.  604 
 605 
Figure 4.  606 
Endoscopic image of a dog with eosinophilic lung disease showing severe mucosal erythema 607 
and inflammation and mild presence of mucus.  608 
 609 
Figure 5.  610 
Endoscopic image of a dog with eosinophilic lung disease showing a large amount of thickened 611 
mucus.  612 
 613 
Figure 6.  614 
Endoscopic image of a dog with eosinophilic lung disease with evidence of severe 615 
bronchiectasis.  616 
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 617 
Figure 7.  618 
Bronchoalveolar lavage cytology of a dog with severe eosinophilic pleocytosis.  619 
 620 
Figure 8.  621 
A breakdown of the corticosteroid treatment administered to the studied eosinophilic lung 622 
disease population of the current study. Immunosuppressive therapy was considered when a 623 
dose equal or more than 1mg/kg per day of prednisolone was administered. Fluticasone was 624 
used in all dogs as inhaled therapy.  625 
 626 
